Bafetinib

DB11851InvestigationalSmall molecule

Bafetinib has been used in trials studying the treatment of Adult Gliosarcoma, Adult Mixed Glioma, Adult Glioblastoma, Chronic Myeloid Leukemia, and Acute Lymphocytic Leukemia, among others.

Mechanism: Pharmacologically active on Tyrosine-protein kinase ABL1 and Tyrosine-protein kinase Lyn
Curator reviewed
Formula / weight: C₃₀H₃₁F₃N₈O · 576.6153 g/mol (avg)
Code names: INNO-406 · NS 187

Resolves to

Compound

UNIINVW4Z03I9BCAS859212-16-1ChEMBLCHEMBL206834PubChem11387605

Structure

InChIKeyZGBAJMQHJDFTQJ-DEOSSOPVSA-NSMILESCN(C)[C@H]1CCN(CC2=C(C=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CN=C3)=C2)C(F)(F)F)C1

Targets

P00519ABL1P07948LYN

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bafetinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account